Mumbai: Mankind Pharma Limited posted robust growth in its standalone Q4 FY26 results, with revenue from operations increasing 22 percent year-on-year to Rs 2,581.8 crore, up from Rs 2,119.5 crore in the same quarter a year earlier.
Net profit surged 203 percent to Rs 713.6 crore from Rs 235.2 crore in Q4 FY25. Profit before tax rose to Rs 788.0 crore, up from Rs 281.5 crore in the same quarter last year.The company’s board has endorsed the audited standalone and consolidated financial statements for the quarter and the full year ended March 31, 2026.
Sequential And Annual Growth
Sequentially, revenue fell 1.9 percent from Rs 2,632.7 crore recorded in Q3 FY26. In contrast, quarterly net profit increased 59 percent from Rs 448.9 crore, driven by reduced tax expenses and improved operating profitability.
Total expenses for the quarter were Rs 1,897.7 crore, compared with Rs 2,057.5 crore in the fourth quarter of FY25. Finance costs declined to Rs 125.3 crore from Rs 165.1 crore in the same period a year earlier.
The quarter also recorded exceptional items amounting to Rs 22.8 crore, primarily arising from the impact of labour codes and stamp duty costs associated with intellectual property transfer agreements.
What Drove The Numbers?
The company stated that the branded generics women’s health division acquired from Bharat Serums and Vaccines was transferred to Mankind Pharma effective November 1, 2025. This deal supported the operational performance for the quarter.
Employee benefit expenses rose sequentially to Rs 550.9 crore from Rs 543.8 crore, while depreciation and amortisation came in at Rs 109.4 crore. Basic earnings per share climbed to Rs 17.29 from Rs 5.70 in the fourth quarter of FY25. Mankind Pharma continues to be reported as a single pharmaceutical segment under Ind AS standards.
Full-Year Performance
In FY26, revenue from operations climbed 9.6 percent to Rs 10,421.2 crore, up from Rs 9,507.4 crore in FY25. Annual net profit advanced 15 percent to Rs 2,037.6 crore, compared with Rs 1,786.0 crore a year earlier.
Profit before tax came in at Rs 2,315 crore, compared with Rs 2,146.5 crore in the previous year. The board also recorded that senior leaders, including Executive Chairman Ramesh Juneja and CEO Sheetal Arora, chose not to receive any commission for FY26 in order to support future business expansion and bolster the company’s cash position.
Disclaimer: This report is based on audited financial results filed by the company and does not constitute investment advice.